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SETTING: Although tuberculosis (TB) is a curable dis-
ease, it remains a major global health problem and an 
important cause of morbidity and mortality among vul-
nerable populations, including refugees and migrants.
OBJECTIVE: To describe results and experiences over 
20 years at a TB programme in refugee camps on the 
Thai-Burmese border in Tak Province, Thailand, and to 
identify risk factors associated with adverse outcomes 
(e.g., default, failure, death).
DESIGN: Retrospective review of routine records of 
2425 patients admitted for TB treatment in the Mae La 
TB programme between May 1987 and December 2005.
RESULTS: TB cases notifi  ed among refugees decreased 
over 20 years. Among patients treated with a fi  rst-, 
s  econd- or third-line regimen, 77.5% had a successful 
outcome, 13.5% defaulted, 7.6% died and 1.3% failed 
treatment. Multivariate analysis for new cases showed 
higher likelihood of adverse outcomes for patients who 
were Burmese migrants or Thai villagers, male, aged 
>15 years or with smear-negative pulmonary TB.
CONCLUSION: These fi   ndings suggest that treatment 
outcomes depend on the programme’s capacity to re-
spond to specifi  c patients’ constraints. High-risk groups, 
such as migrant populations, need a patient-centred ap-
proach, and specifi  c, innovative strategies have to be de-
veloped based on the needs of the most vulnerable and 
marginalised populations.
KEY WORDS:  tuberculosis treatment; refugees; mi-
grants; Thailand
OVER 9 MILLION new tuberculosis (TB) cases and 
about 2 million deaths are reported yearly.1 As 85% 
of refugees and internally displaced persons (IDPs) 
originate from or settle in high TB prevalence coun-
tries, the disease is a particular burden in this popula-
tion.2,3 Specifi  c TB programme strategies have been 
developed for refugee contexts.2,4 In TB programmes 
reporting successful results, common favourable cir-
cumstances include relative political stability in the 
country; provision of basic needs for individuals at 
the start of TB activities; adequately staffed, funded, 
and available medical services; and close collabora-
tion and coordination between aid agencies and na-
tional programmes.5 However, peer-reviewed evidence 
assessing these strategies is scarce.6–8 
Since Myanmar (Burma) gained independence from 
the United Kingdom in 1948, civil war between the 
military government and armed opposition groups has 
resulted in over 1 million deaths and 2 million IDPs, 
predominantly among ethnic minority civilians. Mean-
while, thousands of people have fl  ed ethnic confl  ict to 
fi  nd protection in surrounding countries.9 Since 1984, 
a large number of people have found refuge in camps 
in Thailand. The Thai authorities allowed national and 
international non-governmental organisations (NGOs) 
to provide food, shelter and medical care for these 
refugees. Médecins Sans Frontières (MSF) began pro-
viding assistance to this population during the same 
year and started a TB programme in 1985. 
Here, we describe TB programme outcomes, with 
the objective of identifying risk factors associated 
with poor outcomes. 
METHODS
The refugee camps were located in Tak Province, 
Thailand, 500 km northwest of Bangkok. The esti-
mated refugee population in Tak Province increased 
from 10  000 in 1984 to 80  000 in 2004.10 Refugees 
from Burma were initially resettled in 14 camps along 
the Thai-Burmese border. As part of the policies of the 
Thai authorities, resettlements of the refugees pro-
gressively resulted in the establishment of three larger 
camps: Mae La, Umpiem Mai and Nu Po (Figure 1).
Patients enrolled in the programme belonged to 
three specifi  c groups: refugees from Burma living and 
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registered in the camps, illegal Burmese migrants 
without refugee status, and Thai Karen villagers living 
near the refugee camps. Patients were ethnic Karen, 
Bangladeshi Burmese, and ethnic Burmese. 
At the start of the programme in 1985, patients 
with TB were treated in health facilities located in dif-
ferent camps. In 1988, a TB unit was created in Shoklo 
camp and was relocated in Mae La camp after the 
transfer of refugees from Shoklo to Mae La camp. 
This TB unit was the only clinic offering TB treat-
ment to refugees in the region, as the Thai national 
programme at district hospitals was restricted to Thai 
citizens.
Deﬁ  nitions of cases, treatment and 
  treatment response
Due to missing data for the fi  rst 2 years of the pro-
gramme (63 patients admitted between 1985 and 
1987), only TB cases diagnosed from 14 May 1987 to 
31 December 2005 were included. Case defi  nitions 
were consistent with the World Health Organization 
(WHO) and International Union Against Tuberculo-
sis and Lung Disease (The Union) recommendations 
between 1985 and 2005.11–17 
TB diagnosis was based on smear microscopy of 
three sputum specimens collected over 2 days and 
stained using the hot Ziehl-Neelsen method. X-rays 
and clinical evidence were used to diagnose smear-
negative and extra-pulmonary TB (EPTB). Patients 
were classifi  ed according to the following case defi  ni-
tions: 1) a pulmonary smear-positive patient had 
two smear-positive results, defi  ned as ⩾10 acid-fast 
  bacilli/100 high power fi   elds or one/scanty smear-
positive result and TB clinical and radiological pre-
sentation suggestive of TB; 2) a pulmonary smear-
negative patient had at least three smear-negative 
results, clinical and radiological signs suggestive of 
TB, and absence of clinical improvement after two 
courses of broad-spectrum antibiotics; 3) an EPTB pa-
tient had clinical signs corresponding to active EPTB 
and sputum smear-negative results. A patient with 
both pulmonary and EPTB was defi  ned as a pulmo-
nary case.
Cases were also defi  ned according to their history 
of treatment: patients who had never been treated or 
who had received <1 month of TB treatment in the 
past were defi  ned as new cases, and patients who had 
received ⩾1 month as retreatment cases. Retreatment 
cases included relapses, treatment failures and returns 
after treatment default. As previous treatment was un-
known for patients transferring into the programme, 
transfer patients were classifi  ed as retreatment. Pa-
tients defi  ned as ‘others’, cases not fi  tting the afore-
mentioned defi  nitions, were classifi  ed as retreatment 
cases. Failures of retreatment regimens were defi  ned 
as chronic cases.
Directly observed treatment (DOT) was adminis-
tered daily by health workers. All patients, refugees 
and migrants, were asked to settle within or near 
the camp. The following drugs were used during the 
20 years of the programme: isoniazid (H, INH), ri-
fampicin (R, RMP), pyrazinamide (Z, PZA), etham-
butol (E, EMB), streptomycin (S, SM) and kanamycin 
(K, KM). Treatment regimens were adjusted accord-
ing to international recommendations over time. 
From 1985 to June 1996, a treatment regimen 
consisting of an initial phase of 2 months SHRZ fol-
lowed by 4 months RH was given to new cases.11–13 
During this period, there was no standardised regi-
men for retreatment cases, who received a 9-month 
individualised treatment with fi  rst-line drugs in com-
bination with KM. Between October 1990 and Octo-
ber 1995, 51 patients were treated as retreatment cases 
based on medical decision. Exceptionally, for new 
cases initially treated with SHRZ, the treatment was 
changed to EHRZ, based on medical decision. From 
July 1996 to December 2005, a regimen of 2EHRZ/
4HR was given to new cases, and 2SEHRZ/1RHZE/
5RHE was given to retreatment cases.16,17 Since 2001, 
13 chronic cases have been identifi  ed as multidrug-
resistant TB (MDR-TB) and have received individ-
ualised treatment, including second-line drugs. TB 
Figure 1  Thai-Burmese border map of Karen refugee camps, 
2006. Source: Shoklo Malaria Research Unit, Mae Sot, Tak Prov-
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cultures were performed for particular cases in the 
Siriraj Hospital, Bangkok.
Treatment response was based on sputum smear 
microscopy. Treatment outcomes were defi  ned  as: 
1) cured, for smear-positive patients who completed 
treatment and were sputum smear-negative in the last 
month of treatment and on at least one previous occa-
sion; 2) treatment completed, for patients who com-
pleted treatment but who did not meet the criteria to 
be classifi  ed as a cure or a failure; 3) failure, for 
  patients who remained sputum smear-positive at 
5 months or later during treatment; 4) death, for pa-
tients who died during the course of treatment; 5) de-
fault, for patients whose treatment was interrupted 
for ⩾2 consecutive months; and 6) transferred out, 
for patients who were transferred to another treat-
ment centre and for whom the treatment outcome 
was not known. Treatment success was defi  ned as a 
combination of cured and treatment completed. 
Statistical analysis
Data were collected through retrospective reviews of 
patient medical fi  les and single-entered confi  dentially 
into an electronic database using EpiData (version 
3.1, EpiData Association, Odense, Denmark). Statis-
tical analysis was performed using STATA (version 
9.0, STATA Corporation, College Station, TX, USA). 
The yearly TB case notifi  cation rate was calculated 
for the refugee population using annual population 
data provided by the Thailand Burma Border 
Consortium.
Analysis of outcomes was performed per TB case 
and per patient. For TB case analysis, patients receiv-
ing different regimens for the same TB event (e.g., new 
case and then retreatment case) were counted twice. 
For patient analysis, a patient failing one regimen and 
starting a new regimen for the same TB event was 
counted once. Categorical variables were compared 
with χ2 tests and continuous variables using t-tests.
Failure, death and default were considered adverse 
outcomes. To assess predictors of adverse outcomes 
for new cases, multivariate analysis was conducted 
using Cox regression. Results were presented as ad-
justed hazard ratios (aHRs) with 95% confi  dence in-
tervals (95%CI), and likelihood ratio tests (LRT) 
were performed to test the models. P < 0.05 was con-
sidered statistically signifi  cant. 
As this retrospective analysis reports on pro-
gramme monitoring data, ethical committee approval 
was not sought nor was individual written consent 
obtained. 
RESULTS
Patient characteristics
From January 1985 to December 2005, 2800 patients 
were admitted to the TB treatment programme. Re-
cords were lost for the 63 patients admitted before 
May 1987, and fl  oods destroyed 170 archives of pa-
tients diagnosed between 1 April 1992 and 30 June 
1993. A further 140 patient fi  les were lost over the 
years. Data were thus available for a total of 2425 
patients.
Among these patients, 978 (40%) were refugees 
from Burma living in the camps, 1325 (55%) were 
Burmese migrants and 122 (5%) were Thai villagers 
of Karen ethnicity. The majority of the patients were 
male (68%), and the mean age was 35 years (±14 
standard deviation [SD]). Seventy-eight per cent of pa-
tients had smear-positive pulmonary TB, 15% smear-
negative  pulmonary TB, and 7% EPTB (Table 1). 
Among the 167 patients with EPTB, 44% (n = 74) 
had lymphatic TB, 22% (n = 37) osteoarticular TB, 
14% (n = 23) meningeal TB and 20% other forms of 
EPTB (pleural, intestinal, genitourinary, miliary). Pa-
tients with EPTB were younger than pulmonary TB 
patients (P < 0.001). Smear-positive pulmonary TB 
patients were more likely to be male than smear-
negative (P < 0.001) or EPTB patients (P < 0.001). 
Migrant patients were proportionally more often ad-
mitted with smear-positive pulmonary TB than refu-
gee patients (P < 0.001).
TB case notiﬁ  cation
Overall, the 2425 patients in the programme accounted 
for 2564 TB registered cases: 87% (n = 2231) were 
new cases, 11% (n = 286) retreatment cases and 2% 
(n = 47) chronic cases. Migrant admissions increased 
Table 1  Characteristics of patients by type of TB disease, Mae La TB programme, 1985–2005
Pulmonary 
smear-positive
TB disease
(n = 1904)
n (%)
Pulmonary 
smear-negative
TB disease
(n = 354)
n (%)
Extra-
pulmonary
TB disease
(n = 167)
n (%)
Total
(N = 2425)
n (%)
Age, years, mean ± SD  37.3 ± 13 29.8 ± 16.7 22.6 ± 15.8 35.2 ± 14.5
Male sex 1344 (70.6) 215 (60.7) 87 (52.1) 1646 (67.9)
Origin
Refugees   696 (36.5) 194 (54.8) 88 (52.7)   978 (40.3)
Migrants 1113 (58.4) 139 (39.3) 73 (43.7) 1325 (54.7)
Thai  Karen   95  (5.0)  21  (5.9)  6  (3.6)  122  (5.0)
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from 10 in 1987 to 178 in 2004 (mean 70/year), and 
remained relatively stable for refugees (mean 51/year) 
and Thai Karens (mean 6/year).
The average annual TB case notifi  cation rate among 
the refugee population was estimated at 122 cases per 
100  000 population. TB cases reported in the camps 
increased sharply from the start of the programme 
until 1991 (212/100 000), and then progressively de-
creased to 43/100  000 in 2005 (test for linear trend 
P < 0.001; Figure 2). Notifi  cation rates for 1992 and 
1993 could not be calculated, as patient fi  les were 
missing during parts of this period.
Treatment outcomes
Of the 2231 new cases, 75.5% had a successful out-
come (Table 2). A total of 121 patients (6.9% of 
smear-positive new cases) were considered treatment 
failures and were therefore proposed retreatment reg-
imens. Among the 286 retreatment cases, 62.9% had 
a successful outcome. Of the 47 chronic cases, 13 
were MDR-TB. 
Refugees had lower death and defaulter rates than 
migrants (P = 0.022 and P < 0.001) and Thai Karen 
villagers (P  = 0.016 and P  < 0.001), respectively 
(Table 3). The relative proportion of negative out-
comes increased with the increase in admission of mi-
grant patients to the programme (Figure 3). 
Risk factor analysis
Of the 2231 new cases, we excluded 54 patients incor-
rectly treated with the retreatment regimen. Therefore, 
the analysis was performed on 2177 patients. Multi-
variate analysis showed that female sex, age <15 years, 
refugee status and smear-positive pulmonary TB were 
Table 2  Treatment outcomes for new, retreatment and chronic cases by case deﬁ  nition, Mae La TB programme, 1985–2005
TB type (N =2564)
Cured
n (%)
Treatment 
completed
n (%) 
Failed
n (%)
Died
n (%)
Defaulted
n (%)
Transfer
n (%)
New cases (n = 2231)
Pulmonary smear-positive (n = 1765) 1257 (71.2)   72 (4.1) 121 (6.9) 127 (7.2) 188 (10.6) 0
Pulmonary smear-negative (n =  311)    0 237  (76.2)   0  26  (8.4)  47  (15.1) 1  (0.3)
Extra-pulmonary (n =  155)    0 120  (77.4)   0  10  (6.5)  25  (16.1) 0
Total 1257 (56.3) 429 (19.2) 121 (5.4) 163 (7.3) 260 (11.7) 1 (0.1)
Retreatment cases (n = 286)
Pulmonary smear-positive (n =  230)  129  (56.1)   8  (3.5)  23  (10.0)  12  (5.2)  58  (25.2) 0
Pulmonary smear-negative (n =  44)    0  33  (75.0)   0   4  (9.1)   7  (15.9) 0
Extra-pulmonary (n =  12)    0  10  (83.3)   0   0   2  (16.7) 0
Total  129  (45.1)  51  (17.8)  23  (8.1)  16  (5.6)  67  (23.4) 0
Chronic cases (n = 47)
Pulmonary smear-positive (n =  47)   23  (48.9)   2  (4.3)   5  (10.6)   4  (8.5)  13  (27.7) 0
TB = tuberculosis.
Table 3  Overall patient treatment outcomes by residency 
status, Mae La TB programme, 1985–2005 (n = 2425)
Treatment outcome
Refugees
(n = 978)
n (%)
Migrants*
(n = 1325)
n (%)
Thai Karen
(n = 122)
n (%)
Cured 591 (60.3) 742 (56.1) 68 (55.7)
Treatment completed 253 (25.8) 214 (16.2) 14 (11.5)
Died   57 (5.8) 112 (8.5) 14 (11.5)
Failed  treatment   6  (0.6)  24  (1.8)  1  (0.8)
Defaulted   73 (7.5) 230 (17.4) 25 (20.5)
* Two patients transferred among migrants.
TB = tuberculosis.
Figure 3  Trend of negative outcomes (failure, death or de-
fault) over time (grey bars) and admission of migrant patients 
(grey line), Mae La Tuberculosis Programme, 1985–2005. Pa-
tient records are missing for the period April 1992–June 1993.
Figure 2  Trend of tuberculosis case notiﬁ  cation rate (black 
line) and population in refugee camps (grey bars), Tak Province, 
Thailand, 1985–2005. Patient records are missing for the period 
April 1992–June 1993.20   years   of   treating TB   in   refugees/migrants  1593
predictors of favourable outcomes (Table 4). Excluding 
age, similar associations were found for smear-  positive 
pulmonary cases (n = 1712; data not shown).
DISCUSSION
This retrospective study shows a reduction in TB 
cases notifi  ed over 20 years in a refugee setting. The 
sharp increase in TB cases reported from 1987 to 
1992 was probably due to increased TB case detec-
tion at the beginning of the programme. The TB case 
notifi   cation rate among refugees subsequently de-
creased continuously between 1992 and 2005. Offer-
ing appropriate TB care to a refugee population likely 
contributed to this reduction. The overall improve-
ment in living conditions and nutritional status of the 
refugees also probably contributed to the decrease.
The overall treatment success rate of 77.5% is 
consistent with other studies in refugee settings.6–8 
The low failure rate of 1.3% might have been under-
estimated, as defaulters may also have failed treat-
ment. Despite the absence of systematic TB culture, 
there was no factor suggesting a problem of drug re-
sistance in this population at that time. 
It is important to note that the TB targets sug-
gested by Kessler et al.5 were achieved in the refugee 
population, with the exception of the default rate, 
which remained above the target. The programme 
was less effective in reaching the targets in the mi-
grant and Thai villager populations, who experienced 
high mortality and default rates. Although the overall 
failure rate among new cases was worrisome, these 
cases were retreated and the few failures that re-
mained were concentrated in the migrant group.
Few studies have reported predictors of adverse 
TB treatment outcomes in displaced populations.18,19 
The high death rate of smear-negative patients (around 
9%) could be explained by the existence of human 
immunodefi  ciency virus co-infection.20,21 It may also 
be the consequence of misdiagnosis, as little capacity 
was available in this programme to diagnose smear-
negative pulmonary TB.
As reported elsewhere, we observed a higher pro-
portion of male patients admitted to the programme.1 
The worse outcomes in males is consistent with previ-
ous studies reporting better treatment adherence in 
women.22 Men were more likely than women to work 
outside the camp, thus potentially hindering treat-
ment adherence. 
Burmese migrant patients were more likely to be 
male (P < 0.001) and older (P < 0.001), as mainly 
male adults crossed the border seeking employment 
in Thai factories. They were also more likely to 
have smear-positive pulmonary TB. Compared with 
  refugees, they generally reached health services at 
more advanced stages of the disease, which could also 
explain their worse outcomes. The risk of defaulting 
was increased for Burmese migrants, who were illegal 
in Thailand and, if arrested, were sent back to Myan-
mar where tracing was not possible. 
As this programme was developed initially for ref-
ugees living in a closed camp, it was not well adapted 
to the migrant population. Patients were required to 
remain in the camp for the duration of their DOT-
based treatment, which was not compatible with the 
migratory patterns of temporary workers.23 Previous 
studies have reported that treatment adherence was 
worse among patients separated from their families24 
Table 4  Risk factors associated with adverse outcome for new cases, Mae La TB programme, 
1985–2005 (n = 2177)
Risk factor n
Univariate analysis Multivariate analysis
HR 95%CI P value aHR 95%CI P value
Age, years
<15  147 Reference Reference
15–39 1204 1.84 1.15–2.94 0.011 1.82 1.10–3.01 0.019
40–59  684 2.09 1.30–3.37 0.002 2.01 1.20–3.36 0.008
⩾60  142 2.21 1.28–3.84 0.005 2.15 1.20–3.84 0.010
Sex
Female  701 Reference Reference
Male 1476 1.45 1.19–1.76 <0.001 1.33 1.09–1.62 0.005
Residency status
Refugee  928 Reference Reference
Migrant 1137 1.86 1.52–2.28 <0.001 1.80 1.46–2.21 <0.001
Thai Karen   112 2.45 1.71–3.52 <0.001 2.34 1.63–3.36 <0.001
TB type
Smear-positive 1712 Reference Reference
Smear-negative  310 1.08 0.84–1.39 0.54 1.38 1.06–1.80 0.017
Extra-pulmonary  155 0.82 0.58–1.17 0.27 1.20 0.83–1.73 0.34 
Regimen
SHRZ  577 Reference
EHRZ 1477 0.78 0.48–1.28 0.33
TB = tuberculosis; HR = hazard ratio; CI = conﬁ  dence interval; aHR = adjusted HR; S = streptomycin; H = isoniazid; 
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and among non-refugee patients engaged in working 
activities, compared with refugees living in a camp 
under assistance.5
Patients living in villages around the camps were 
essentially from the Karen ethnic group. Absence of 
regular Thai identifi   cation papers, language and 
health costs were barriers to accessing mainstream 
health services. In this programme, however, they 
could communicate in their own language and had 
free access to health care. Nevertheless, they had 
worse TB treatment outcomes than refugees. A previ-
ous study in Khartoum, Sudan, reported worse out-
comes in patients living outside an IDP camp com-
pared with patients living in the camp.25 Unlike 
refugees, villagers have to rely on their own work for 
survival, as they receive only partial support from 
aid agencies.
A number of limitations should be mentioned. The 
quality of retrospectively collected data was inconsis-
tent over time. Some patients may have concealed 
previous TB treatment at admission and thus have 
been misclassifi  ed as new cases, which could explain 
some poor outcomes of new cases. Also, several socio-
logical factors that might predispose groups of pa-
tients to an adverse outcome were not addressed. 
Prospective qualitative studies should continue to in-
vestigate sociological and behavioural aspects such 
as family support, literacy, and drinking or smoking 
habits, which may infl  uence patient outcomes. 
CONCLUSIONS
This retrospective cohort study shows a reduction of 
TB cases reported over 20 years in a refugee popula-
tion, in a programme providing adequate quality of 
care and relief aid, adapted to the specifi  c needs of a 
resettled refugee population. Nevertheless, the pro-
gramme was less effective in adequately treating mi-
grants and Thai Karen villagers, with specifi  cities not 
directly addressed by the programme. These popula-
tions would better benefi  t from a patient-centred ap-
proach with TB care delivery adapted to their needs. 
More fl   exible strategies, such as self-administered 
treatment or community-based models, can be effec-
tive if strong counselling and support are provided, as 
well as home-based follow-up. New drugs to shorten 
the length of treatment are urgently needed to improve 
adherence, especially for vulnerable populations liv-
ing in unstable contexts.
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CONTEXTE :    Malgré le fait qu’elle soit une maladie cu-
rable, la tuberculose (TB) reste un problème de santé 
publique majeur et une cause importante de morbidité et 
de mortalité chez les populations les plus vulnérables, 
incluant les réfugiés et les migrants.
OBJECTIF :    Décrire les résultats de plus de 20 ans 
d’expérience d’un programme de TB dans des camps de 
réfugiés à la frontière thaï-birmane dans la Province de 
Tak en Thaïlande et identifi  er les facteurs de risque as-
sociés à un résultat défavorable (perdu de vue, échec, 
décès).
MÉTHODE :  Revue rétrospective des dossiers individuels 
de 2425 patients admis pour le traitement de la TB dans 
le programme TB de Mae La, entre mai 1987 et décem-
bre 2005.
RÉSULTATS :    Les cas de TB notifi  és parmi les réfugiés 
ont diminué au cours des 20 ans. Parmi les patients traités 
avec un régime de première, seconde ou troisième ligne, 
77,5% ont eu un résultat positif, 13,5% ont été perdus 
de vue, 7,6% sont morts et 1,3% ont échoué. L’analyse 
multivariée des nouveaux cas a montré une plus haute 
probabilité de résultats défavorables chez les migrants 
birmans ou les villageois thaïs, les patients de sexe mas-
culin, les patients âgés de plus de 15 ans, ou ceux avec 
une TB pulmonaire à frottis négatif.
CONCLUSION :  Ces résultats suggèrent que le succès du 
traitement dépend de la capacité du programme à répon-
dre aux contraintes spécifi  ques des patients. Les groupes 
à haut risque, comme les populations de migrants, doi-
vent bénéfi  cier d’une approche centrée sur le patient. Des 
nouvelles stratégies innovatrices doivent être dévelop-
pées spécifi  quement en considérant les besoins des popu-
lations les plus vulnérables et marginalisées.
MARCO DE REFERENCIA:    La tuberculosis (TB), pese a 
que es una enfermedad curable, representa todavía un 
problema considerable de salud pública y una causa impor-
tante de morbilidad y mortalidad en las poblaciones vul-
nerables, que incluyen a los refugiados y a los inmigrantes.
OBJETIVO:  Describir los resultados y la experiencia ad-
quirida en más de 20 años de ejecución de un programa 
de atención de la TB en un campo de refugiados en la 
frontera entre Tailandia y Myanmar en la provincia Tak 
de Tailandia y defi  nir los factores de riesgo de desenlaces 
desfavorables (es decir, abandono, fracaso y muerte).
MÉTODO:  Se llevó a cabo un estudio retrospectivo de los 
registros sistemáticos de 2425 pacientes inscritos al pro-
grama de atención de la TB del campo Mae La entre 
mayo de 1987 y diciembre del 2005.
RESULTADOS:  La notifi  cación de casos de TB en los re-
fugiados disminuyó en los 20 años. De los pacientes 
tratados con una pauta de primera, segunda o tercera 
línea, 77,5% alcanzaron un desenlace clínico exitoso; 
13,5% abandonaron; 7,6% fallecieron; y 1,3% tuvieron 
un fracaso terapéutico. El análisis multifactorial de los 
casos nuevos puso en evidencia una probabilidad mayor 
de desenlaces desfavorables en los pacientes migrantes 
de Myanmar y los habitantes tailandeses de la población, 
los hombres, los mayores de 15 años y los casos de TB 
pulmonar con baciloscopia negativa.
CONCLUSIÓN:    Estos resultados indican que los desen-
laces terapéuticos dependen de la capacidad del pro-
grama a responder a las difi  cultades específi  cas de los 
pacientes. Los grupos de mayor riesgo, como las pobla-
ciones migrantes, exigen un enfoque centrado en el pa-
ciente y se precisa establecer estrategias específi  cas e in-
novadoras con base en las necesidades de los grupos más 
vulnerables y marginadas.
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